IL254792A0 - New pyridinium compounds - Google Patents

New pyridinium compounds

Info

Publication number
IL254792A0
IL254792A0 IL254792A IL25479217A IL254792A0 IL 254792 A0 IL254792 A0 IL 254792A0 IL 254792 A IL254792 A IL 254792A IL 25479217 A IL25479217 A IL 25479217A IL 254792 A0 IL254792 A0 IL 254792A0
Authority
IL
Israel
Prior art keywords
pyridinium compounds
new
new pyridinium
compounds
pyridinium
Prior art date
Application number
IL254792A
Other languages
Hebrew (he)
Other versions
IL254792B (en
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of IL254792A0 publication Critical patent/IL254792A0/en
Publication of IL254792B publication Critical patent/IL254792B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126Acids containing more than four carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IL254792A 2015-04-08 2017-09-28 Novel pyridinium compounds IL254792B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1473MU2015 2015-04-08
PCT/IB2016/051917 WO2016162785A1 (en) 2015-04-08 2016-04-05 Novel pyridinium compounds

Publications (2)

Publication Number Publication Date
IL254792A0 true IL254792A0 (en) 2017-12-31
IL254792B IL254792B (en) 2021-01-31

Family

ID=55808799

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254792A IL254792B (en) 2015-04-08 2017-09-28 Novel pyridinium compounds

Country Status (19)

Country Link
US (2) US10233175B2 (en)
EP (1) EP3280711A1 (en)
JP (1) JP6782763B2 (en)
KR (1) KR20170134661A (en)
CN (1) CN107438604B (en)
AR (1) AR104274A1 (en)
AU (1) AU2016245418B2 (en)
BR (1) BR112017021631A2 (en)
CA (1) CA2997364A1 (en)
EA (1) EA035406B1 (en)
IL (1) IL254792B (en)
MX (1) MX381854B (en)
MY (1) MY182914A (en)
PH (1) PH12017501830A1 (en)
SG (1) SG11201708140RA (en)
TW (1) TWI710559B (en)
UA (1) UA120389C2 (en)
WO (1) WO2016162785A1 (en)
ZA (1) ZA201707090B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017021631A2 (en) * 2015-04-08 2018-07-03 Torrent Pharmaceuticals Limited compound, pharmaceutical composition, pharmaceutical combination, method of treatment, use of a compound and process for preparing said compound
RS63124B1 (en) 2018-03-08 2022-05-31 Incyte Corp Aminopyrazine diol compounds as pi3k-y inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US20200338058A1 (en) * 2019-04-28 2020-10-29 King Faisal University Therapeutic agents for treating and preventing autoimmune diseases and cancer and a screening method
WO2022238921A1 (en) * 2021-05-14 2022-11-17 Torrent Pharmaceuticals Limited In-situ synthesis of 3-substituted pyridinium compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL348049A1 (en) * 1999-10-06 2002-05-06 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the treatment of diabetic and aging−related vascular complications
AU769940B2 (en) * 1999-10-06 2004-02-12 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
US6608094B2 (en) * 1999-10-06 2003-08-19 Torrent Pharmaceuticals Ltd. Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
EP1243581B1 (en) 2001-03-21 2005-07-13 Torrent Pharmaceuticals Ltd Pyridinium compounds useful for the treatment of AGE-related diseases
MXPA03008089A (en) 2001-04-05 2004-01-22 Torrent Pharmaceuticals Ltd Heterocyclic compounds for aging-related and diabetic vascular complications.
JP2003137783A (en) * 2001-10-19 2003-05-14 Torrent Pharmaceuticals Ltd Composition and method for using pyridinium derivative for cosmetic and therapeutic application
BRPI0708507A2 (en) 2006-03-03 2011-05-31 Torrent Pharmaceuticals Ltd NEW DOUBLE ACTION RECEIVERS (DARA) ANTAGONISTS FOR AT1 ETA RECEPTORS
US20110034378A1 (en) * 2008-01-25 2011-02-10 Chaitanya Dutt Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc.
BR112017021631A2 (en) * 2015-04-08 2018-07-03 Torrent Pharmaceuticals Limited compound, pharmaceutical composition, pharmaceutical combination, method of treatment, use of a compound and process for preparing said compound

Also Published As

Publication number Publication date
MX381854B (en) 2025-03-13
SG11201708140RA (en) 2017-11-29
EA035406B1 (en) 2020-06-09
UA120389C2 (en) 2019-11-25
CN107438604A (en) 2017-12-05
EP3280711A1 (en) 2018-02-14
CN107438604B (en) 2021-12-03
JP2018511658A (en) 2018-04-26
IL254792B (en) 2021-01-31
US10233175B2 (en) 2019-03-19
JP6782763B2 (en) 2020-11-11
AR104274A1 (en) 2017-07-12
EA201792234A1 (en) 2018-02-28
BR112017021631A2 (en) 2018-07-03
AU2016245418A1 (en) 2017-11-02
CA2997364A1 (en) 2016-10-13
US20180118728A1 (en) 2018-05-03
PH12017501830A1 (en) 2018-04-23
TWI710559B (en) 2020-11-21
WO2016162785A1 (en) 2016-10-13
MX2017012943A (en) 2018-01-30
US10717727B2 (en) 2020-07-21
TW201639834A (en) 2016-11-16
MY182914A (en) 2021-02-05
AU2016245418B2 (en) 2020-03-26
KR20170134661A (en) 2017-12-06
ZA201707090B (en) 2021-03-31
US20190169175A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
NL301311I2 (en) sugemalimab
FIC20240028I1 (en) Retifanlimab
NL301262I2 (en) Pirtobrutinib
FIC20230012I1 (en) Teklistamab
NL301216I2 (en) vutrisiran
LT3197883T (en) NEW COMPOUNDS
LT3134402T (en) 4-AMINO-IMIDAZOCHINOLINE COMPOUNDS
DK3283625T3 (en) NUCLEASE-MEDIED GENOMEDITING
PT3298027T (en) ANTELMINTHIC DEPSYPEPTIDE COMPOUNDS
DK3331869T3 (en) MUSCARINAGONISTS
LT3464336T (en) COMPOUNDS
BR112016030730A2 (en) Compound
EP3395436A4 (en) microreactor
CL2016002165A1 (en) Aminocarbonylcarbamate compounds
LT3362444T (en) COMPOUNDS
DK3597189T3 (en) CRYSTALLINIC COMPOUNDS
DK3292136T3 (en) PENICILLIN-G-ACYLASER
DK3191466T3 (en) AZETIDINYLOXYPHENYLPYRROLIDINE COMPOUNDS
EP3396460A4 (en) SCRAPER
IL254792A0 (en) New pyridinium compounds
HUE039805T2 (en) New sulfonylaminobenzamide compounds
DK3347403T3 (en) POLYALCOXYFATT COMPOUND
DE102015206660A8 (en) Beamsaw
EP3396467A4 (en) SCRAPER
LT3331885T (en) COMPOUNDS

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed